Untitled

Marttin, E.; Verhoef, J.; Cullander, Christopher; Romeijn, Stefan; Nagelkerke, J. Fred; Merkus, F. W. H. M.

doi:10.1023/a:1012109329631

Cited by 50 publications

(6 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cyclodextrins may affect nasal mucosal membranes in the same manner, thus allowing their extended use as adjuvants to improve the nasal absorption of poorly absorbable peptide and protein drugs. The lipid solubilization mediated by cyclodextrins may cause changes in transcellular processes, and these changes are believed to be transmitted to the paracellular region, which appears to be the most likely route for the transport of polypeptides. , …”

Section: Hydrophilic Cyclodextrins As Absorption Enhancersmentioning

confidence: 99%

Cyclodextrin Drug Carrier Systems

1998

View full text Add to dashboard Cite

Section: Hydrophilic Cyclodextrins As Absorption Enhancersmentioning

confidence: 99%

Cyclodextrin Drug Carrier Systems

1998

View full text Add to dashboard Cite

“…Recently, it has been shown that intranasal MMP-9 can be used as a local nasal permeability enhancer [ 116 ]. It is important to keep in mind that nasal permeability enhancers cause significant nasal irritation and mucosal toxicity [ 117 ], and additional studies are needed.…”

Section: Discussionmentioning

confidence: 99%

FcRn as a Transporter for Nasal Delivery of Biologics: A Systematic Review

Fieux

Quellec

Bartier

et al. 2021

IJMS

View full text Add to dashboard Cite

FcRn plays a major role in regulating immune homeostasis, but it is also able to transport biologics across cellular barriers. The question of whether FcRn could be an efficient transporter of biologics across the nasal epithelial barrier is of particular interest, as it would allow a less invasive strategy for the administration of biologics in comparison to subcutaneous, intramuscular or intravenous administrations, which are often used in clinical practice. A focused systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. It was registered on the international prospective register of systematic reviews PROSPERO, which helped in identifying articles that met the inclusion criteria. Clinical and preclinical studies involving FcRn and the nasal delivery of biologics were screened, and the risk of bias was assessed across studies using the Oral Health Assessment Tool (OHAT). Among the 12 studies finally included in this systematic review (out of the 758 studies screened), 11 demonstrated efficient transcytosis of biologics through the nasal epithelium. Only three studies evaluated the potential toxicity of biologics’ intranasal delivery, and they all showed that it was safe. This systematic review confirmed that FcRn is expressed in the nasal airway and the olfactory epithelium, and that FcRn may play a role in IgG and/or IgG-derived molecule-transcytosis across the airway epithelium. However, additional research is needed to better characterize the pharmacokinetic and pharmacodynamic properties of biologics after their intranasal delivery.

show abstract

“…The concomitant intranasal administration of ( 125 I)I-IgG and MMP-9 significantly improved the uptake of antibody into the brain as compared to unformulated antibody ( Kumar et al, 2018 ). However, permeability enhancers should be used with caution as mucosal irritation and toxicity has been reported ( Maher et al, 2016 ; Marttin et al, 1997 ). Another method consists in improving transcellular transport using cell-penetrating peptides: short-length (5–30 amino-acids) peptides, rich in positive charges and containing hydrophobic tryptophan residues may help translocation across epithelium.…”

Section: Fcrn and Cellular Barriersmentioning

confidence: 99%

Therapeutic antibodies – natural and pathological barriers and strategies to overcome them

Ojaimi

Blin

Lamamy

et al. 2022

Pharmacology & Therapeutics

View full text Add to dashboard Cite

Antibody-based therapeutics have become a major class of therapeutics with over 120 recombinant antibodies approved or under review in the EU or US. This therapeutic class has experienced a remarkable expansion with an expected acceleration in 2021–2022 due to the extraordinary global response to SARS-CoV2 pandemic and the public disclosure of over a hundred anti-SARS-CoV2 antibodies. Mainly delivered intravenously, alternative delivery routes have emerged to improve antibody therapeutic index and patient comfort. A major hurdle for antibody delivery and efficacy as well as the development of alternative administration routes, is to understand the different natural and pathological barriers that antibodies face as soon as they enter the body up to the moment they bind to their target antigen. In this review, we discuss the well-known and more under-investigated extracellular and cellular barriers faced by antibodies. We also discuss some of the strategies developed in the recent years to overcome these barriers and increase antibody delivery to its site of action. A better understanding of the biological barriers that antibodies have to face will allow the optimization of antibody delivery near its target. This opens the way to the development of improved therapy with less systemic side effects and increased patients’ adherence to the treatment.

show abstract

Untitled

Abstract: Confocal laser scanning microscopy is a suitable approach to visualize the transport pathways of high molecular weight hydrophilic compounds across nasal epithelium, and to study the effects of absorption enhancers on drug transport and cell morphology.

Cited by 50 publications

References 15 publications

Cyclodextrin Drug Carrier Systems

Cyclodextrin Drug Carrier Systems

FcRn as a Transporter for Nasal Delivery of Biologics: A Systematic Review

Therapeutic antibodies – natural and pathological barriers and strategies to overcome them

Contact Info

Product

Resources

About